Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 11:44am CET

JOHANNESBURG - Aspen yesterday welcomed the Competition Commission's decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commission’s initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts “due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable”.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. “In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany,” the commission said.

“It is, therefore, unlikely that the price charged by Equity could pass the test for excessive pricing.” The commission, however, alleged that Roche and Genentech had engaged in excessive pricing, price discrimination and exclusionary conduct in the provision of breast cancer medicine in South Africa, adding that breast cancer treatment was unaffordable in South Africa.

The commission said investigations on Pfizer for excessive pricing of lung cancer medication in South Africa would continue. The drug maker was the only provider of a lung cancer treatment medication, known asXalkori (crizotinib), in South Africa. The body also alleged that lung cancer treatment in South Africa was unaffordable.

Aspen shares fell 0.01 percent on the JSE yesterday to close at R304.75 a share.


(c) BusinessReport 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
01/17 ROCHE : Niger gov's wife express dismay over poor cancer care
01/17 MERCK AND : Keytruda aces another lung cancer study
01/17 MERCK AND : Mercks Keytruda combo wows again, acing PhIII overall survival goal ..
01/17 Pfizer Joins Foundation Medicine to Develop Cancer CDx
01/17 Pfizer puts Foundation Medicine at the center of its cancer companion diagnos..
01/17 ROCHE : Forty Seven Inc. and Genentech work together for Leukemia and Bladder Ca..
01/16 ROCHE : EU Approves Roche`s OCREVUS for Relapsing Forms of MS
01/15 BIOGEN : Roche's Ocrevus receives EU approval for MS
01/13 ROCHE : Genentech beefs up its PD-L1 combo pipeline, signing the dont eat me spe..
More news
News from SeekingAlpha
01/17 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Merck's Keytruda Rises, Celgene's Possibl..
01/16 Roche Achieves Another Milestone With Ocrevus
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/15 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's MS Win, Aradigm FDA Panel Woes, A..
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
Financials ( CHF)
Sales 2017 53 462 M
EBIT 2017 18 174 M
Net income 2017 11 159 M
Debt 2017 9 887 M
Yield 2017 3,64%
P/E ratio 2017 17,62
P/E ratio 2018 16,14
EV / Sales 2017 3,99x
EV / Sales 2018 3,77x
Capitalization 204 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 274  CHF
Spread / Average Target 16%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-5.33%211 361
JOHNSON & JOHNSON4.32%394 542
NOVARTIS1.41%227 089
PFIZER0.88%218 162
MERCK AND COMPANY10.31%169 287
AMGEN6.41%134 685